Pregnancy under everolimus-based immunosuppression
نویسندگان
چکیده
منابع مشابه
Pediatric renal transplantation under tacrolimus-based immunosuppression.
BACKGROUND Tacrolimus has been used as a primary immunosuppressive agent in adult and pediatric renal transplant recipients, with reasonable outcomes. Methods. Between December 14, 1989 and December 31, 1996, 82 pediatric renal transplantations alone were performed under tacrolimus-based immunosuppression without induction anti-lymphocyte antibody therapy. Patients undergoing concomitant or pri...
متن کاملKidney transplantation under FK 506 immunosuppression.
W E RECENTLY reported our initial experience with FK 506 in 36 patients undergoing renal transplan-tation. 1 This series was characterized by a high average complexity. and included 10 patients who also were liver recipients either concomitantly or at an earlier time. Additionally , 2 of the 10 also were given a heart or pancreas. We report here a follow-up of the 26 patients from that original...
متن کاملRenal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis.
OBJECTIVES Calcineurin inhibitor-induced nephrotoxicity reduces long-term patient survival after heart transplant. Proliferation signal inhibitors, in combination with or replacing calcineurin inhibitors, may preserve or improve renal function. We evaluated the effect of calcineurin inhibitor-reduction and withdrawal in everolimus-based immunosuppression on renal function after a heart transpla...
متن کاملA randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients
Kidney transplant recipients receiving calcineurin inhibitor-based immunosuppression incur increased long-term risks of cancer and kidney fibrosis. Switch to mammalian target of rapamycin (mTOR) inhibitors may reduce these risks. Steroid or Cyclosporin Removal After Transplant using Everolimus (SOCRATES), a 36-month, prospective, multinational, open-label, randomized controlled trial for de nov...
متن کاملEfficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients
For cardiac transplant (CTx) recipients, the recommended everolimus (EVL) dose is 0.75 mg bid or 1.5 mg bid and the target trough blood level is 3-8 μg/L. We studied a cohort of 56 CTx patients with chronic kidney disease receiving 0.75 mg bid EVL to maintain blood levels of 5-8 ug/L (designated RD group) and a cohort of 51 CTx patients with chronic kidney disease receiving 0.5 mg bid to mainta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Transplant International
سال: 2011
ISSN: 0934-0874
DOI: 10.1111/j.1432-2277.2011.01356.x